CD151 drives cancer progression depending on integrin α3β1 through EGFR signaling in non-small cell lung cancer.

Based on these results, we demonstrated a new mechanism of CD151-mediated tumor progression by targeting EGFR/ErbB2 signaling pathway, by which CD151 promotes NSCLC proliferation, migration, and invasion, which may considered as a potential target of NSCLC treatment.